About AVID200 and the AVID200-02 Trial AVID200 is an isoform-selective and highly potent inhibitor ... the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR ...

"Working with Rigel and having access to their TGF beta receptor kinase inhibitors extends our existing portfolio of immunotherapeutic approaches to include this key mediator of immunosuppression ...

"This collaboration places our TGF beta receptor kinase inhibitor program into the hands of Bristol-Myers Squibb, a premier immuno-oncology company. Together, we believe TGF beta inhibition may ...